单次曲普瑞林植入治疗中枢性性早熟可持续有效 2 年。
A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
机构信息
Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN.
出版信息
J Pediatr. 2013 Oct;163(4):1214-6. doi: 10.1016/j.jpeds.2013.05.033. Epub 2013 Jul 1.
Abstract
We investigated whether a "yearly" histrelin implant would provide pubertal suppression when left in place for 2 years. Equivalent suppression was observed when comparing 12 and 24 months in 33 children with central precocious puberty. A single implant for 2 years reduces cost and number of implant procedures.
摘要
我们研究了在放置 2 年的情况下，“每年”一次的曲普瑞林埋植是否可以提供青春期抑制。在 33 名中枢性性早熟儿童中，比较 12 个月和 24 个月时，观察到了等效的抑制效果。2 年使用单根埋植可降低成本和埋植次数。
相似文献
1
A single histrelin implant is effective for 2 years for treatment of central precocious puberty.单次曲普瑞林植入治疗中枢性性早熟可持续有效 2 年。
J Pediatr. 2013 Oct;163(4):1214-6. doi: 10.1016/j.jpeds.2013.05.033. Epub 2013 Jul 1.
2
Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.采用促性腺激素释放激素类似物治疗中枢性性早熟的患儿，常出现黄体生成素的不规则分泌，仍保持青春期前的状态。
J Pediatr. 2013 Mar;162(3):562-5. doi: 10.1016/j.jpeds.2012.08.038. Epub 2012 Oct 3.
3
Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.用于治疗中枢性性早熟的醋酸组氨瑞林皮下植入剂一年一次长期持续抑制：一项3期多中心试验的最终报告
J Clin Endocrinol Metab. 2015 Jun;100(6):2354-63. doi: 10.1210/jc.2014-3031. Epub 2015 Mar 24.
4
Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.组氨瑞林皮下植入剂治疗儿童中枢性性早熟的疗效与安全性：一项多中心试验
J Clin Endocrinol Metab. 2007 May;92(5):1697-704. doi: 10.1210/jc.2006-2479. Epub 2007 Feb 27.
5
The histrelin implant: a novel treatment for central precocious puberty.组氨瑞林植入剂：一种治疗中枢性性早熟的新方法。
Pediatrics. 2005 Dec;116(6):e798-802. doi: 10.1542/peds.2005-0538.
6
Experience with the Histrelin Implant in Pediatric Patients.小儿患者使用组氨瑞林植入剂的经验。
Endocr Dev. 2016;30:54-9. doi: 10.1159/000439330. Epub 2015 Dec 10.
7
Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.游离α亚基是促性腺激素释放激素治疗中枢性性早熟后促性腺激素恢复的最敏感标志物。
J Clin Endocrinol Metab. 2010 Jun;95(6):2841-4. doi: 10.1210/jc.2009-2078. Epub 2010 Mar 25.
8
Time to menarche and final height after histrelin implant treatment for central precocious puberty.促性腺激素释放激素类似物治疗中枢性性早熟患者的初潮时间和最终身高。
J Pediatr. 2013 Aug;163(2):532-6. doi: 10.1016/j.jpeds.2013.01.021. Epub 2013 Feb 26.
9
The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.美国国立卫生研究院（NIH）对性早熟的研究经验：诊断亚组及对短期促黄体生成素释放激素类似物治疗的反应
J Pediatr. 1986 Jan;108(1):47-54. doi: 10.1016/s0022-3476(86)80767-3.
10
Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty.在中枢性性早熟患者中使用单一组氨瑞林植入物超过一年的长期经验。
J Pediatr Endocrinol Metab. 2023 Jan 11;36(3):309-312. doi: 10.1515/jpem-2022-0557. Print 2023 Mar 28.
引用本文的文献
1
Height benefits after GnRHa treatment in girls aged over 6 years with central precocious puberty: a meta-analysis.6岁以上中枢性性早熟女童GnRHa治疗后的身高获益：一项荟萃分析
Endocrine. 2025 Jun 23. doi: 10.1007/s12020-025-04332-6.
2
Adult height in girls with idiopathic central precocious puberty treated with triptorelin.用曲普瑞林治疗的特发性中枢性性早熟女孩的成年身高
Front Endocrinol (Lausanne). 2024 Dec 5;15:1498726. doi: 10.3389/fendo.2024.1498726. eCollection 2024.
3
Supporting Transgender, Nonbinary, and Gender Diverse Youth During Solid Organ Transplantation.在实体器官移植过程中支持跨性别、非二元性别和性别多样化的青少年。
Pediatr Transplant. 2025 Feb;29(1):e14864. doi: 10.1111/petr.14864.
4
Extended Use of Histrelin Implant in Pediatric Patients.促性腺激素释放激素类似物植入剂在儿科患者中的长期使用。
Transgend Health. 2023 Jun 1;8(3):264-272. doi: 10.1089/trgh.2021.0130. eCollection 2023 Jun.
5
Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States.美国用于中枢性性早熟儿童的促性腺激素释放激素类似物疗法
Front Pediatr. 2022 Oct 4;10:968485. doi: 10.3389/fped.2022.968485. eCollection 2022.
6
Transgender Youth Experiences with Implantable GnRH Agonists for Puberty Suppression.跨性别青少年使用可植入促性腺激素释放激素激动剂抑制青春期的经历。
Transgend Health. 2022 Aug 1;7(4):364-368. doi: 10.1089/trgh.2021.0006. eCollection 2022 Aug.
7
Gonadotropin Suppression for 7 Years After a Single Histrelin Implant for Precocious Puberty.单次注射组氨瑞林治疗性早熟后性腺激素抑制长达7年
J Endocr Soc. 2022 Jan 7;6(2):bvab189. doi: 10.1210/jendso/bvab189. eCollection 2022 Feb 1.
8
Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape.可植入药物递送系统与异物反应：审视当前临床现状
Bioengineering (Basel). 2021 Dec 9;8(12):205. doi: 10.3390/bioengineering8120205.
9
Approach to the Patient: Pharmacological Management of Trans and Gender-Diverse Adolescents.患者处理：跨性别和性别多样化青少年的药理学管理。
J Clin Endocrinol Metab. 2022 Jan 1;107(1):241-257. doi: 10.1210/clinem/dgab634.
10
The association between family impact and health-related quality of life of children with idiopathic central precocious puberty in Chongqing, China.中国重庆特发性中枢性性早熟儿童的家庭影响与健康相关生活质量之间的关联。
Health Qual Life Outcomes. 2021 Jun 26;19(1):171. doi: 10.1186/s12955-021-01805-w.
本文引用的文献
1
Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.采用促性腺激素释放激素类似物治疗中枢性性早熟的患儿，常出现黄体生成素的不规则分泌，仍保持青春期前的状态。
J Pediatr. 2013 Mar;162(3):562-5. doi: 10.1016/j.jpeds.2012.08.038. Epub 2012 Oct 3.
2
Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.使用12个月的醋酸亮丙瑞林植入剂治疗中枢性性早熟第二年的治疗结果。
Int J Pediatr Endocrinol. 2009;2009:812517. doi: 10.1155/2009/812517. Epub 2009 Feb 26.
3
Consensus statement on the use of gonadotropin-releasing hormone analogs in children.关于儿童使用促性腺激素释放激素类似物的共识声明。
Pediatrics. 2009 Apr;123(4):e752-62. doi: 10.1542/peds.2008-1783. Epub 2009 Mar 30.
4
Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.组氨瑞林皮下植入剂治疗儿童中枢性性早熟的疗效与安全性：一项多中心试验
J Clin Endocrinol Metab. 2007 May;92(5):1697-704. doi: 10.1210/jc.2006-2479. Epub 2007 Feb 27.
5
The histrelin implant: a novel treatment for central precocious puberty.组氨瑞林植入剂：一种治疗中枢性性早熟的新方法。
Pediatrics. 2005 Dec;116(6):e798-802. doi: 10.1542/peds.2005-0538.
Zotero 插件